ABBVIE INC (4AB.DE) Stock Price, Quote, News and Overview
FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR
4AB.DE Quote, Performance and Key Statistics
FRA:4AB (7/18/2025, 7:00:00 PM)
163.4
-0.8 (-0.49%)
The current stock price of 4AB.DE is 163.4 EUR. In the past month the price increased by 1.11%. In the past year, price increased by 3.77%.
4AB.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMG.DE | AMGEN INC | 14.21 | 137.04B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.03 | 116.61B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 102.50B | ||
| ARGX.BR | ARGENX SE | 106.49 | 30.04B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.69B | ||
| IDP.DE | BIOGEN INC | 7.94 | 15.90B | ||
| 0QF.DE | MODERNA INC | N/A | 10.56B | ||
| 1MRNA.MI | MODERNA INC | N/A | 10.54B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 1SRPT.MI | SAREPTA THERAPEUTICS INC | N/A | 1.64B | ||
| YTSN.DE | KUROS BIOSCIENCES AG-REG | N/A | 1.18B | ||
| 5CV.DE | CUREVAC NV | 5.72 | 1.04B |
Related stock screener links
About 4AB.DE
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
ABBVIE INC / 4AB.DE FAQ
What is the stock price of ABBVIE INC today?
The current stock price of 4AB.DE is 163.4 EUR. The price decreased by -0.49% in the last trading session.
What is the ticker symbol for ABBVIE INC stock?
The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 4AB.DE stock listed?
4AB.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ABBVIE INC stock?
34 analysts have analysed 4AB.DE and the average price target is 188.78 EUR. This implies a price increase of 15.53% is expected in the next year compared to the current price of 163.4. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABBVIE INC worth?
ABBVIE INC (4AB.DE) has a market capitalization of 288.63B EUR. This makes 4AB.DE a Mega Cap stock.
How many employees does ABBVIE INC have?
ABBVIE INC (4AB.DE) currently has 55000 employees.
What are the support and resistance levels for ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a support level at 163.38 and a resistance level at 164.88. Check the full technical report for a detailed analysis of 4AB.DE support and resistance levels.
Is ABBVIE INC (4AB.DE) expected to grow?
The Revenue of ABBVIE INC (4AB.DE) is expected to grow by 6.86% in the next year. Check the estimates tab for more information on the 4AB.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABBVIE INC (4AB.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 4AB.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 4AB.DE, evaluating the profitability, health, valuation and growth aspects
- ABBVIE INC (4AB.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABBVIE INC (4AB.DE) Sales and EPS estimates to see what analysts future expectations are.
- ABBVIE INC (4AB.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABBVIE INC (4AB.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABBVIE INC (4AB.DE) Stock Chart to make your own analysis
- ABBVIE INC (4AB.DE) Latest news and press-releases to stay up to date.
Does ABBVIE INC (4AB.DE) stock pay dividends?
ABBVIE INC (4AB.DE) has a dividend yield of 3.36%. The yearly dividend amount is currently 5.34. Check the full fundamental report for a detailed analysis of 4AB.DE dividend history, reliability and sustainability.
When does ABBVIE INC (4AB.DE) report earnings?
ABBVIE INC (4AB.DE) will report earnings on 2025-07-31, before the market open.
What is the Price/Earnings (PE) ratio of ABBVIE INC (4AB.DE)?
The PE ratio for ABBVIE INC (4AB.DE) is 18.42. This is based on the reported non-GAAP earnings per share of 8.87 and the current share price of 163.4 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 4AB.DE.
4AB.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE turns out to be only a medium performer in the overall market: it outperformed 45.39% of all stocks.
4AB.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. While 4AB.DE has a great profitability rating, there are quite some concerns on its financial health.
4AB.DE Financial Highlights
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 8.87. The EPS decreased by -6.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.24% | ||
| ROA | 3.05% | ||
| ROE | 292.61% | ||
| Debt/Equity | 46.56 |
4AB.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 22.41% and a revenue growth 6.86% for 4AB.DE